Comparative Pharmacology
Head-to-head clinical analysis: CLINORIL versus EC NAPROSYN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLINORIL versus EC NAPROSYN.
CLINORIL vs EC-NAPROSYN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, thereby exerting anti-inflammatory, analgesic, and antipyretic effects. Sulindac is a prodrug converted to the active sulfide metabolite.
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
150-200 mg orally twice daily, with maximum daily dose of 400 mg.
500-1000 mg orally twice daily; maximum 1500 mg/day.
None Documented
None Documented
7.8 hours (terminal); clinical context: prolonged in elderly and renal impairment, requiring dose adjustment.
Terminal elimination half-life 12-17 hours (mean 14 hours); prolonged in elderly and renal impairment
Renal: 50% as unchanged drug, 25% as glucuronide conjugate; Biliary/Fecal: 25% as metabolites.
Renal (95%) as unchanged drug (10%) and conjugated metabolites (60%) and other metabolites (25%); biliary/fecal (5%)
Category C
Category C
NSAID
NSAID